Drug trio found to block tumour resistance in pancreatic cancer
8 days ago
- #drug-combination
- #pancreatic-cancer
- #preclinical-research
- A triple-targeted drug combination shows promise in inducing complete regression of pancreatic tumours in preclinical models.
- The therapy targets RAF1, EGFR family receptors, and STAT3 signalling pathways to overcome treatment resistance.
- Drugs used in the combination include RMC-6236 (daraxonrasib), Afatinib, and SD36.
- The treatment demonstrated significant tumour regression in mouse models and human cancer tissues (PDX).
- The combination therapy was well-tolerated in animals, suggesting a favourable safety profile for future clinical trials.
- The approach aims to prevent tumour resistance by attacking multiple signalling nodes simultaneously.
- Findings could guide the development of new clinical trials for pancreatic ductal adenocarcinoma (PDAC) patients.